Wave Life Sciences Ltd
Wave Life Sciences Ltd., a clinical-stage biotechnology company, designs, develops, and commercializes ribonucleic acid (RNA) medicines through PRISM, a discovery and drug development platform. The company's RNA medicines platform, PRISM, combines multiple modalities, chemistry innovation, and deep insights into human genetics to deliver scientific breakthroughs that treat both rare and prevalent… Read more
Market Cap & Net Worth: Wave Life Sciences Ltd (WVE)
Wave Life Sciences Ltd (NASDAQ:WVE) has a market capitalization of $2.31 Billion ($2.31 Billion) as of March 18, 2026. Listed on the NASDAQ stock exchange, this USA-based company holds position #6923 globally and #3790 in its home market, demonstrating a -6.25% decrease in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Wave Life Sciences Ltd's stock price $12.46 by its total outstanding shares 185759908 (185.76 Million).
Wave Life Sciences Ltd Market Cap History: 2015 to 2026
Wave Life Sciences Ltd's market capitalization history from 2015 to 2026. Data shows change from $2.96 Billion to $2.31 Billion (-2.39% CAGR).
Index Memberships
Wave Life Sciences Ltd is a constituent of 3 market indices:
| Index | Total Market Cap | Weight (%) | Rank by Market Cap |
|---|---|---|---|
|
NASDAQ Health Care
IXHC
|
$2.24 Trillion | 0.05% | #192 of 976 |
|
NASDAQ Composite
IXIC
|
$33.39 Trillion | 0.00% | #789 of 3165 |
|
NASDAQ Biotechnology
NBI
|
$1.54 Trillion | 0.07% | #120 of 263 |
Weight: Wave Life Sciences Ltd's market cap as a percentage of total index value. Rank: Position among all constituents by market cap.
Wave Life Sciences Ltd Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Wave Life Sciences Ltd's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance.
Latest Price to Sales (P/S) Ratio
21.22x
Wave Life Sciences Ltd's market cap is 21.22 times its annual revenue
1728.56x
Lower than industry averageLatest Price to Earnings (P/E) Ratio
N/A
P/E ratio not applicable due to negative or zero earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2015 | $2.96 Billion | $152.00K | -$19.20 Million | 19492.57x | N/A |
| 2016 | $4.86 Billion | $1.49 Million | -$55.40 Million | 3271.13x | N/A |
| 2017 | $6.52 Billion | $3.70 Million | -$102.03 Million | 1760.31x | N/A |
| 2018 | $7.81 Billion | $14.41 Million | -$146.65 Million | 541.79x | N/A |
| 2019 | $1.49 Billion | $15.98 Million | -$193.64 Million | 93.15x | N/A |
| 2020 | $1.46 Billion | $20.08 Million | -$149.91 Million | 72.82x | N/A |
| 2021 | $583.29 Million | $40.96 Million | -$122.25 Million | 14.24x | N/A |
| 2022 | $1.30 Billion | $3.65 Million | -$161.82 Million | 356.35x | N/A |
| 2023 | $938.09 Million | $113.31 Million | -$57.51 Million | 8.28x | N/A |
| 2024 | $2.30 Billion | $108.30 Million | -$97.01 Million | 21.22x | N/A |
Competitor Companies of WVE by Market Capitalization
Companies near Wave Life Sciences Ltd in the global market cap rankings as of March 18, 2026.
Key companies related to Wave Life Sciences Ltd by market ranking:
- Vertex Pharmaceuticals Inc (NASDAQ:VRTX): Ranked #162 globally with a market cap of $117.09 Billion USD.
- Regeneron Pharmaceuticals Inc (NASDAQ:REGN): Ranked #281 globally with a market cap of $74.80 Billion USD.
- CSL Limited (PINK:CMXHF): Ranked #344 globally with a market cap of $63.46 Billion USD.
- argenx SE (OTCGREY:ARGNF): Ranked #500 globally with a market cap of $42.99 Billion USD.
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #162 | Vertex Pharmaceuticals Inc | NASDAQ:VRTX | $117.09 Billion | $462.49 |
| #281 | Regeneron Pharmaceuticals Inc | NASDAQ:REGN | $74.80 Billion | $759.05 |
| #344 | CSL Limited | PINK:CMXHF | $63.46 Billion | $149.87 |
| #500 | argenx SE | OTCGREY:ARGNF | $42.99 Billion | $697.42 |
Wave Life Sciences Ltd Historical Marketcap From 2015 to 2026
Between 2015 and today, Wave Life Sciences Ltd's market cap moved from $2.96 Billion to $ 2.31 Billion, with a yearly change of -2.39%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | $2.31 Billion | -26.71% |
| 2025 | $3.16 Billion | +37.43% |
| 2024 | $2.30 Billion | +144.95% |
| 2023 | $938.09 Million | -27.86% |
| 2022 | $1.30 Billion | +122.93% |
| 2021 | $583.29 Million | -60.10% |
| 2020 | $1.46 Billion | -1.81% |
| 2019 | $1.49 Billion | -80.93% |
| 2018 | $7.81 Billion | +19.77% |
| 2017 | $6.52 Billion | +34.23% |
| 2016 | $4.86 Billion | +63.95% |
| 2015 | $2.96 Billion | -- |
End of Day Market Cap According to Different Sources
On Mar 18th, 2026 the market cap of Wave Life Sciences Ltd was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $2.31 Billion USD |
| MoneyControl | $2.31 Billion USD |
| MarketWatch | $2.31 Billion USD |
| marketcap.company | $2.31 Billion USD |
| Reuters | $2.31 Billion USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.